Asahi Kasei Therapeutics won FDA approval for Hovilpri (approved for treating lesions caused by herpes simplex virus infection), a daily oral pill that follows the company’s acquisition of AiCuris Anti-Infective Cures for about $919 million. The approval adds a regulated, commercially actionable antiviral option to Asahi Kasei’s portfolio and validates the acquired program pathway—coming after a deal that signaled long-term commitment to anti-infectives. For the broader market, the timing highlights how late-stage development and regulatory execution can rapidly turn large M&A bets into revenue-generating assets.